CURALEAF HOLDINGS INC (CURA.TO)

Key Updates

Curaleaf Holdings (CURA.TO) has advanced 10.25% to $14.73 since the August 10 report, extending the strong upward momentum that began in early August. This price-driven move occurs without fresh company-specific news in the interim, but follows a busy period of retail expansion announcements and the ongoing public dispute with Aurora Cannabis regarding the pending acquisition offer. The stock is now trading at its highest level since the post-reverse-split rally peaked in early July, having fully recovered the late-July correction that had pulled shares down to $12.12.

Current Trend

Year-to-date performance stands at +43.99%, with the stock up 63.12% over the past six months. The current price of $14.73 sits above all key moving averages, reflecting a sustained uptrend that has been punctuated by two sharp corrections (the -20.84% decline in late July and the subsequent recovery). The 1-month gain of 7.28% and 5-day gain of 4.84% indicate accelerating momentum. The stock has now reclaimed and exceeded the $15.31 level reached on July 2, which previously marked the post-split high, suggesting the early-July peak may act as the next resistance level. Support is established at the $13.36 level from the August 10 report and more firmly at the $12.12 low from late July.

Investment Thesis

The investment thesis remains centered on Curaleaf's aggressive retail expansion strategy and the potential value creation from the pending acquisition of Aurora Cannabis. The company has opened four new dispensaries since late August (Cutler Bay, Riverview, Port Richey, and Fishtown), bringing its nationwide footprint to 179 locations, with Florida alone now at 78 stores. Management continues to emphasize Florida and Pennsylvania as key growth markets. The Aurora acquisition saga remains a significant overhang, with Curaleaf actively pursuing regulatory intervention to halt Aurora's ATM share issuance program, which Curaleaf argues is diluting shareholders and increasing acquisition costs. The company has publicly challenged Aurora's operational performance and fiscal 2027 guidance, positioning its US$4.00 per share offer as a premium that Aurora shareholders should evaluate without defensive tactics.

Thesis Status

The investment thesis is intact and has strengthened since the last report. The price recovery to $14.73 confirms that the late-July selloff was a correction within an uptrend rather than a trend reversal. Retail expansion continues at a steady pace, with four store openings announced in the past month, demonstrating execution on the growth strategy. The Aurora acquisition remains a catalyst with clear upside potential, though it also carries execution risk. The company's willingness to escalate the regulatory battle with Aurora through the Alberta Securities Commission application shows management's conviction in the deal's value proposition. No negative developments have emerged since the last report; the primary risk remains the unresolved status of the Aurora offer and the potential for prolonged regulatory proceedings.

Key Drivers

• Retail expansion: Four new dispensary openings announced since late August (Cutler Bay, Riverview, Port Richey, Fishtown), expanding the footprint to 179 locations nationwide, with Florida now at 78 stores and Pennsylvania holding steady at 18. Source: PR Newswire, PR Newswire, PR Newswire, PR Newswire
• Aurora acquisition: Curaleaf filed an application with the Alberta Securities Commission to halt Aurora's ATM program, citing shareholder dilution of approximately 10.8% since February 2026 and increased acquisition costs exceeding US$11 million. Source: PR Newswire
• Public dispute with Aurora: Curaleaf has publicly rebutted Aurora's characterizations, highlighting Aurora's 35% share decline over the past year versus Curaleaf's 56% gain, and Aurora's June quarter adjusted EBITDA drop of 63% quarter-over-quarter. Source: PR Newswire

Technical Analysis

The stock is trading at $14.73, up 10.25% since the August 10 report. Price action shows a clear V-shaped recovery from the $12.12 low in late July, with the stock now approaching its July 2 high of $15.31. The 5-day gain of 4.84% and 1-month gain of 7.28% demonstrate accelerating upward momentum. YTD performance of +43.99% places the stock firmly in a bullish trend. Key resistance sits at $15.31 (July 2 high); a breakout above this level would signal a new post-split high and likely extend the uptrend. Immediate support is at $13.36 (August 10 level), with stronger support at $12.12 (July 29 low). The stock has successfully defended the $12-$13 range twice since the split, suggesting a solid base has formed. Volume patterns and the sustained upward trajectory over six months (+63.12%) indicate institutional accumulation. The 10.25% move since the last report occurred without fresh company news, suggesting either short-covering or renewed investor confidence in the Aurora deal outcome.

Bull Case

• Retail expansion momentum is strong: Four new dispensaries opened in September alone, bringing the total to 179 locations nationwide, with Florida reaching 78 stores and additional openings planned through year-end. CEO Boris Jordan has explicitly stated Florida's importance as a medical cannabis market. Source: PR Newswire, PR Newswire
• Relative outperformance versus Aurora: Curaleaf's shares rose approximately 56% over the past year while Aurora's declined approximately 35%, demonstrating superior operational execution and shareholder value creation. Source: PR Newswire
• Regulatory escalation shows conviction: The Alberta Securities Commission application to halt Aurora's ATM program demonstrates management's commitment to completing the acquisition at a fair price, potentially removing a significant overhang. Source: PR Newswire
• Product portfolio expansion: New dispensaries are stocking proprietary brands including Select Briq 2 vape devices, Grassroots, FIND, Dark Heart, and Reef flower, supporting revenue diversification and customer retention. Source: PR Newswire, PR Newswire
• Strategic market positioning: Pennsylvania remains a key medical cannabis market per CEO Boris Jordan, and the Fishtown relocation represents continued investment in this important state, maintaining 18 stores there. Source: PR Newswire

Bear Case

• Aurora acquisition uncertainty persists: The deal remains unresolved, with Aurora refusing to sign a non-disclosure agreement or host a site visit, and the regulatory application could face delays or rejection, leaving the acquisition overhang unresolved. Source: PR Newswire, PR Newswire
• Dilution risk from Aurora's ATM program: Aurora has issued approximately 2.81 million shares at an average price of US$3.04 per share since Curaleaf expressed acquisition interest, potentially undermining the deal economics and increasing the overall acquisition cost by more than US$11 million. Source: PR Newswire
• Integration and execution risk: The proposed acquisition of a company with declining operational metrics (Aurora's June quarter adjusted EBITDA fell 63% quarter-over-quarter with negative operating cash flow of C$4.4 million) could create integration challenges and drag on Curaleaf's financial performance. Source: PR Newswire
• Valuation concerns at current levels: The stock has risen 63.12% over six months and 43.99% YTD, and the recent 10.25% move occurred without fresh fundamental news, suggesting the market may be pricing in deal completion that remains uncertain. Source: PR Newswire
• Regulatory and legal costs: The escalating dispute with Aurora, including the Alberta Securities Commission application, could result in prolonged legal proceedings, management distraction, and costs that may not be recoverable if the deal fails. Source: PR Newswire